Patients with prehypertension - do we have enough evidence to treat them?

Current Vascular Pharmacology

Volumn 12, Issue 4, 2014, Pages 586-597

  Marta, Michalska ^a   Zanchetti, Alberto ^b   Wong, Nathan D ^c   Malyszko, Jolanta ^d   Rysz, Jacek ^a   Banach, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Blood pressure; Cardiovascular risk; High normal blood pressure; Hypertension; Prehypertension; Risk stratification

Indexed keywords

ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; DISEASE COURSE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NONHUMAN; PREHYPERTENSION; ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COMPLICATION; DIET THERAPY; DRUG EFFECTS; EXERCISE; PRACTICE GUIDELINE; RISK; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; EXERCISE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREHYPERTENSION; RISK; WEIGHT REDUCTION PROGRAMS;

EID: 84904724190     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990126     Document Type: Article

References (130)

1. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158.
2. Lewington S, Clarke R, Qizilbash N. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
3. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
4. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-46.
5. Cifkova R, Erdine S, Fagard R, et al. ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physi-cians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21: 1779-86.
6. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682-1686.
7. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of HypertensionEuropean Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
8. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society Guidelines. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18, 3: 139-85.
9. Banach M, Rysz J. Current problems in hypertension and nephrology. Expert Opin Pharmacother 2010; 11(16): 2575-8.
10. Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
11. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
12. PROGRESS Collaborative Study Group: Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
13. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke. Kidney Int 2002; 61: 1086-1097.
14. Barylski M, Mayszko J, Rysz J, My liwiec M, Banach M. Lipids, blood pressure, kidney-what was new in 2011? Arch Med Sci 2011; 7(6): 1055-66
15. Pimenta E, Oparil S. Prehypertension: epidemiology, consequences and treatment. Nat Rev Nephrol 2010; 8: 21-30.
16. Ostrowski F, Artyszuk, Lewandowski J, Gaciong Z. High normal blood pressure-clinical fact or myth? Arterial Hypertens 2008; 12: 374-381.
17. Banach M, Aronow WS. Hypertension therapy in the older adultsdo we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Hum Hypertens 2012; 26(11): 641-3.
18. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US Adults According to the New Joint National Committee guidelines. Arch Intern Med 2004; 164: 2126-2134.
19. Lloyd-Jones D, Adams R, Carnethon M, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 21-181.
20. Agyemang C, van Valkengoed I, van den Born BJ, Stronks K. Prevalence and determinants of prehypertension among African Surinamese, Hindustani Surinamese, and White Dutch in Amsterdam, the Netherlands: The SUNSET study. Eur J Cardiovasc Prev Rehabil 2007; 14: 775-781.
21. Choi KM, Park HS, Han JH, et al. Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens 2006; 24: 1515-1521.
22. Ishikawa Y, Ishikawa J, Ishikawa S, et al. Prevalence and determinants of prehypertension in a Japanese general population: The Jichi Medical School Cohort Study. Hypertens Res 2008; 31: 1323-1330.
23. Liu LK, Peng LN, Chen LK, Hwang SJ, Chiou ST. Prehypertension among middle-aged and elderly people in Taiwan: A five-year follow-up. J Atheroscler Thromb 2010; 17: 189-194.
24. Grotto I, Grossman E, Huerta M, Sharabi Y. Prevalence of prehypertension and associated cardiovascular risk profiles among young Israeli adults. Hypertension 2006; 48: 254-259.
25. Janghorbani M, Amini M, Gouya MM, Delavari A, Alikhani S, Mahdavi A. Nationwide survey of prevalence and risk factors of prehypertension and hypertension in Iranian adults. J Hypertens 2008; 26: 419-426.
26. Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006; 119: 133-141.
27. Liszka HA, Mainous AG, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. Ann Fam Med 2005; 3: 294-299.
28. Banach M, Aronow WS. Blood pressure j-curve: current concepts. Curr Hypertens Rep 2012; 14: 556-66.
29. Kokubo Y, Kamide K. High-normal blood pressure and the risk of cardiovascular disease. Circ J 2009; 73: 1381-1385.
30. Wu S, Huang Z, Yang X, et al. Cardiovascular events in a prehypertensive Chinese population: Four-year follow-up study. Int J Cardiol 2012 (in print).
31. Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohamed Y. Is prehypertension a risk factor for cardiovascular disease? Stroke 2005; 36: 1859-1863.
32. Banach M, Kjeldsen SE, Narkiewicz K. Editorial. Controversies in Hypertension Treatment. Curr Vasc Pharmacol 2010; 8: 731-732.
33. Gu Q, Burt VL, Palose-Ram R, Yoon S, Gillum RF. High blood pressure and cardiovascular disease mortality and risk among US adults: the Third National Health and Nutrition Examination Survey Mortality Follow-Up Study. Ann Epidemiol 2008; 18: 302-309.
34. Hsia J, Margolis KL, Eaton CB, et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 2007; 115: 855-860.
35. Hansen TW. Staessen JA, Zhang H, et al. Cardiovascular outcome in relation to progression to hypertension in the Copenhagen MONICA cohort. Am J Hypertens 2007; 20: 483-491.
36. Zhang W, Li N. Prevalence, risk factors, and management of prehypertension. Int J Hypertens 2011; 2011: 605359.
37. Vulic D, Loncar S, Krneta M, et al. Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska, Bosnia and Herzegovina in 2005-2006. Arch Med Sci 2010; 6: 183-7.
38. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. Curr Cardiovasc Risk Rep 2011; 5: 174-179.
39. Greenlund KJ, Croft JB, Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. Arch Intern Med 2004; 164: 2113-2118.
40. Wu SL, Zhang ZQ, Song SB, et al. Prevalence of prehypertension and associated cardiovascular risk: two years follow up results. Chin J Epidemiolo 2010; 38, 5: 415-419.
41. Isezuo SA, Sabir AA, Ohwovorilole AE, Fasanmade OA. Prevalence, associated factors and relationship between prehypertension and hypertension: a study of two ethnic African populations in Northern Nigeria. J Hum Hypertens 2011; 25: 224-230.
42. Stpie M, Wlaze RN, Paradowski M, et al. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo-and hypertensive patients-pilot study. Arch Med Sci 2012; 8: 431-6
43. Stepien M, Rosniak-Bak K, Paradowski M, et al. Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results. Med Sci Monit 2011; 17(11): PR13-18.
44. Gordon L, Ragoobirsingh D, Morrison E, McGrowder D, ChooKang E, Martorell E. Dyslipidaemia in hypertensive obese type 2 diabetic patients in Jamaica. Arch Med Sci 2010; 6(5): 701-8.
45. Zhang Y, Lee ET, Devereux RB, Yeh J, Best LG, Fabsitz RR, Howard BV: Prehypertension, diabetes, and cardiovascular disease risk in a population-Based Sample: The Strong Heart Study. Hypertension 2006; 47: 410-414.
46. Player MS, Mainous AG, Diaz VA, Everett CJ. Prehypertension and insulin resistance in a nationally representative adult population. J Clin Hypertens 2007; 9: 424-429.
47. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease. Int J Cardiol 2013; 164(2): 141-50.
48. Cordero A, Laclaustra M, León M, et al. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry Substudy. Am J Hypertens 2006; 19: 189-196.
49. Barylski M, Kowalczyk E, Banach M, Ciecwierz J, Pawlicki L, Kowalski J. Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome. Angiology 2009; 60(1): 87-92.
50. Grotto I, Grossman E, Huerta M, Sharabi Y. Prevalence of prehypertension and associated cardiovascular risk profiles among young Israeli adults. Hypertension 2006; 48: 254-259.
51. Srinivasan SR, Myers L, Berenson GS. Changes in metabolic syndrome variables since childhood in prehypertensive and hypertensive subjects. The Bogalusa Heart Study. Hypertension 2006; 48: 33-39.
52. Israeli E, Schochat T, Korzets Z, Tekes-Manova D, Bernheim J, Golan E. Prehypertension and obesity in adolescents population study. Am J Hypertens 2006; 19: 708-712.
53. Zhuo S, Wen W, Li-Yuan M, Shu-Yu W, Yi-Xin W. Home blood pressure measurement in prehypertension and untreated hypertension: comparison with ambulatory blood pressure monitoring and office blood pressure. Blood Press Monit 2009; 14: 245-50.
54. Shimbo D, Newman JD, Schwartz JE. Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass: the Masked Hypertension Study. Am J Hypertens 2012; 25: 664-71.
55. Pierdomenico SD, Pannarale G, Rabbia F, et al. Prognostic relevance of masked hypertension in subjects with prehypertension. Am J Hypertens 2008; 21: 879-83.
56. King DE, Egan BM, Mainous AG. Geesey ME. Elevation of Creactive protein in people with prehypertension. J Clin Hypertens 2004 (Greenwich); 6: 562-568.
57. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens 2004; 17: 568-573.
58. Gluba A, Bielecka A, Mikhailidis DP, et al. An update on biomarkers of heart failure in hypertensive patients. J Hypertens 2012; 30(9): 1681-9.
59. Mercando AD, Lai HM, Aronow WS, et al. Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. Arch Med Sci 2012; 8(1): 57-62.
60. Chiolero A, Cachat F, Burnier M, Paccaud F, Bovet P. Prevalance of hypertension in schoolchildren based on repeated measurements and association with overweight. J Hypertens 2007; 25: 2209-22017.
61. McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr 2007; 150: 640-644.
62. Banach M, Michalska M, Kjeldsen SE, Mayszko J, Mikhailidis DP, Rysz J. What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother 2011; 12(12): 1835-44.
63. Ciakowska-Rysz A, Kowalczyk M, Gottwald L, Kamierczak-Łukaszewicz S. The comparison of common cancer types and the coincidence of concomitant chronic diseases between palliative home care patients in Lodz Voivodeship and the general Polish population. Arch Med Sci. 2012; 8(3):496-503
64. Genovesi S, Giussani M, Pieruzzi F, et al. Results of blood pressure screening in a population of schoolaged children in the province of Milan: role of overweight. J Hypertens 2005; 23: 493-497.
65. Alagiakrishnan K, Banach M, Jones LG, Datta S, Ahmed A, Aronow WS. Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. Ann Med 2013; 45(1): 37-50.
66. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in schoolaged children. Pediatrics 2004; 113: 475-482.
67. Banach M, Aronow WS. Should we have any doubts about hypertension therapy in elderly patients?: ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Pol Arch Med Wewn 2011; 121(7-8): 253.
68. Antal M, Regöly-Mérei A, Nagy K, et al. Representative study for the evaluation of age-and gender-specific anthropometric parameters and blood pressure in an adolescent Hungarian population. Ann Nutr Metab 2004; 48: 307-313.
69. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics 1996; 98(4 Pt 1): 649-58.
70. Saleh EA, Mahfouz AA, Tayel KY, Naguib MK, Bin-al-Shaikh NM. Hypertension and its determinants among primary-school children in Kuwait: an epidemiological study. East Mediterr Health J 2000; 6: 333-337.
71. Redwine KM, Acosta AA, Poffenbarger T, Portman RJ, Samuels J. Development of hypertension in adolescents with pre-hypertension. J Pediatr 2012; 160, 1: 98-103.
72. Urbina EM, Khoury PR, McCoy C, Daniels SR, Kimball TR, Dolan LM. Cardiac and vascular consequences of pre-hypertension in youth. J Clin Hypertens (Greenwich) 2011; 13(5): 332-42.
73. DeLoach SS, Townsend RR. Vascular Stiffness: Its Measurement and Significance for Epidemiologic and Outcome Studies. Clin J Am Soc Nephrol 2008; 3: 184-192.
74. Gedikli O, Kiris A, Ozturk S, et al. Effects of prehypertension on arterial stiffnes and wave reflections. Clin Exp Hypertens 2010; 32: 84-89.
75. Myradal A, Gan LM, Osika W, Friberg P, Johansson M. Increased intima thickness of the radial artery inindividuals with prehypertension and hypertension. Atherosclerosis 2010; 209: 147-151.
76. Tomiyama H, Yamashina A. Arterial stiffness in prehypertension: a possible vicious cycle. Cardiovasc Transl Res 2012; 5, 3: 280-286.
77. Stepie M, Banach M, Jankowski P, Rysz J. Clinical implications of non-invasive measurement of central aortic blood pressure. Curr Vasc Pharmacol 2010; 8(6): 747-52.
78. Tomiyama H, Matsumoto C, Yamada J, Yoshida M, Odaira M, Shiina K, Nagata M, Yamashina A. Predictors of progression from prehypertension to hypertension in Japanese men. Am J Hypertens 2009; 22: 630-636.
79. Di Bello V, Talini E, Dell'Omo G, et al. Early left ventricular mechanics abnormali-ties in prehypertension: a two-dimensional strain echocardiography study. Am J Hypertens 2010; 23: 405-412.
80. Rogowicz-Frontczak A, Araszkiewicz A, Pilacinski S, ZozulinskaZiolkiewicz D, Wykretowicz A, Wierusz-Wysocka B. Carotid intima-media thickness and arterial stiffness in type 1 diabetic patients with and without microangiopathy. Arch Med Sci 2012; 8(3): 484-90.
81. Drukteinis JS, Roman MJ, Fabsitz RR, et al. Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolesce and young adults: The Strong Heart Study. Circulation 2007; 115: 221-227.
82. Markus MR, Stritzke J, Lieb W, et al. Implications of persistent prehypertension for ageing-related changes in left ventricular geometry and function: the MONICA/KORA Augsburg study. J Hypertens 2008; 26: 2040-2049.
83. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U. S. adults. Ann Intern Med 2004; 140: 167-174.
84. Jcsiċ M. Sajiċ S. Jcśiċ M, el al. Microalbuminuria in relation to metabolic control and blood pressure in adolescents with type 1 diabetes. Arch Med Sc i 2011: 7(6): 1037-41.
85. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 1999; 34: 973-995.
86. Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: why, who and when? Expert Opin Pharmacother 2010; 11(16): 2665-74.
87. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33: 225-234.
88. Lee JE, Kim YG, Choi YH, Huh W, Kim DJ, Oh HY. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 2006; 47: 962-967.
89. Athyros VG, Hatzitolios AI, Karagiannis A, et al. IMPERATIVE Collaborative Group. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011; 7(6): 984-92.
90. Kaplan NM. Treating Prehypertension: A Review of the Evidence. Curr Hypertens Rep 2008; 10(4): 326-329.
91. Selassie A, Wagner S, Laken ML, LaFrance Ferguson M, Ferdinand KC, Egan BM. Response to Prehypertension: To Treat or Not To Treat Should No Longer Be the Question. Hypertension 2012; 59: 28.
92. Mellen PB, Gao SK, Vitolins MZ, Goff DC Jr. Deteriorating dietary habits among adults with hypertension: DASH dietary accordance, NHANES 1988-1994 and 1999-2004. Arch Intern Med 2008; 168: 308-314.
93. Mensah GA. Eliminating disparities in cardiovascular health: six strategic imperatives and a framework for action. Circulation 2005; 111: 1332-1336.
94. Selassie A, Wagner CS, Laken ML, Ferguson ML, Ferdinand KC, Egan BM. Progression is accelerated from prehypertension to hypertension in blacks. Hypertension 2011; 58, 4: 579-587.
95. Glasser SP, Judd S, Basile J, et al. Prehypertension, racial prevalence and its association with risk factors: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Am J Hypertens 2011; 24(2): 194-9.
96. Czernichow S, Zanchetti A, Turnbull F, et al. Blood Pressure Lowering Treatment Trialists' Collaboration. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 2011; 29: 4-16.
97. Sipahi I, Swaminathan A, Natesan V, Debanne SM, Simon DI, Fang JC. Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials. Stroke 2012; 43, 2: 432-440.
98. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 2011; 305: 913-22.
99. Zanchetti A. Hypertension: meta-analyses: first-rank evidence or second-hand information? Nat Rev Cardiol 2011; 8: 249-251.
100. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62: 347-504.
101. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-1474.
102. Julius S, Nesbitt SD, Egan BM, et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354, 16: 1685-1697.
103. Lüders S, Schrader J, Berger J, et al. PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensinconverting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008; 26: 1487-1496.
104. Symonides B, Jdrusik P, Artyszuk L, GryboA, Dziliski P, Gaciong Z. Different diagnostic criteria significantly affect the rates of hypertension in 18-year-old high school students. Arch Med Sci 2010; 6: 689-94
105. Guo X, Zheng L, Zhang X, et al. The prevalence and heterogeneity of prehypertension: a meta-analysis and meta-regression of published literature worldwide. Cardiovasc J Afr 2012; 23: 44-50.
106. Guo X, Zou L, Zhang X, Li J, Zheng L, Sun Z, Hu J, Wong ND, Sun Y. Prehypertension: a meta-analysis of the epidemiology, risk factors, and predictors of progression. Tex Heart Inst J 2011; 38: 643-52.
107. Márquez-Celedonio FG, Téxon-Fernández O, Chávez-Negrete A, Hernández-López S, Marín-Rendón S, Berlín-Lascurain S. Clinical effect of lifestyle modification on cardiovascular risk in prehypertensives: PREHIPER I study. Rev Esp Cardiol 2009; 62, 86-90.
108. Elmer PJ, Obarzanek E, Vollmer WM, et al. PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006; 144, 485-495.
109. Stevens VJ, Corrigan SA, Obarzanek E, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993; 153: 849-858.
110. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42, 5: 878-884.
111. Cocco G, Pandolfi S. Physical exercise with weight reduction lowers blood pressure and improves abnormal left ventricular relaxation in pharmacologically treated hypertensive patients. J Clin Hypertens 2011; 13, 1: 23-29.
112. Karanja NM, Obarzanek E, Lin PH, et al. Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop Hypertension Trial. DASH Collaborative Research Group. J Am Diet Assoc 1999; 99(suppl 8): S19-S27.
113. Chou CL, Lai YH, Lin TY, Lee TJ, Fang TC. Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats. Arch Med Sci 2011; 7(5): 882-8.
114. Michalska M, Gluba A, Mikhailidis DP, et al. The role of polyphenols in cardiovascular disease. Med Sci Monit 2010; 16(5): RA110-9.
115. Sacks FM, Obarzanek E, Windhauser MM, et al. DASH Investigators. Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH). Ann Epidemiol 1995; 5: 108-118.
116. Appel LJ, Moore TJ, Obarzanek E, et al. DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336: 1117-1124.
117. Hummel SL, Seymour EM, Brook RD, et al. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension 2012; 60(5): 1200-6.
118. Miura K, Okuda N, Turin TC, et al. NIPPON DATA80/90 Research Group. Dietary salt intake and blood pressure in a representative Japanese population: baseline analyses of NIPPON DATA80. J Epidemiolo 2010; 20 (suppl 3): S524-S530.
119. Sacks FM, Svetkey LP, Vollmer WM, et al. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 3-10.
120. Stevens VJ, Obarzanek E, Cook NR, et al. Trials of Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001; 134: 1-11.
121. Cogswell ME, Zhang Z, Carriquiry AL, et al. Sodium and potassium intakes among US adults: NHANES 2003-2008. Am J Clin Nutr 2012; 96: 647-57.
122. Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial. Circulation 2009; 119: 2026-2031.
123. Simeunovic S, Milincic Z, Nikolic D, et al. Physical activity evaluation in Yugoslav Study of the Precursors of Atherosclerosis in School Children-YUSAD study. Arch Med Sci 2010; 6(6): 874-8.
124. Aronow WS, Banach M. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Press 2012; 21(1): 3-5.
125. Braith RW, Pollock ML, Lownthal DT, Graves JE, Limacher MC. Moderate and high intensity exercise lowers blood pressure in normotensive subjects 60 to 79 years of age. Am J Cardiol 1994; 73: 1124-1128.
126. Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure: A meta-analysis of randomized controlled trials. Hypertension 2000; 35: 838-843.
127. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136: 493-503.
128. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001; 38: 1112-7.
129. Puddey IB, Beilin LJ. Alcohol is bad for blood pressure. Clin Exp Pharmacol Physiol 2006; 33, 9: 847-852.
130. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27: 923-934.